National Health Investors (NHI) Shares Sink as Hilliard Lyons Cuts to Underperform
Tweet Send to a FriendGet Alerts NHI Hot Sheet
Price: $71.40 +0.37%
Rating Summary:
1 Buy, 3 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 35 | New: 23
Rating Summary:
1 Buy, 3 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 35 | New: 23
Trade NHI Now!
Shares of National Health Investors (NYSE: NHI) have tumbled in afternoon trade Thursday as Hilliard Lyons' John Roberts just issued an intraday downgrade on the stock. Roberts now rates National Health Investors shares an Underperform, down from Neutral previously.
The downgrade follows Q4 results and FY12 guidance Wednesday afternoon.
Shares of National Health Investors are now down 1.1 percent to $48.18.
For an analyst ratings summary and ratings history on National Health Investors click here. For more ratings news on National Health Investors click here.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
The downgrade follows Q4 results and FY12 guidance Wednesday afternoon.
Shares of National Health Investors are now down 1.1 percent to $48.18.
For an analyst ratings summary and ratings history on National Health Investors click here. For more ratings news on National Health Investors click here.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- UPDATE: Applied Materials, Inc. (AMAT) Tops Q2 EPS by 3c, Offers Guidance
- Goldman Sachs Downgrades Deere (DE) to Sell, Sees 5% Downside
- UPDATE: Aruba Networks, Inc. (ARUN) Misses Q3 EPS by 4c, Guidance Light
Create E-mail Alert Related Categories
DowngradesRelated Entities
Hilliard Lyons, EarningsLogin with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!

